Fig. 3From: Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combinationThe best change from baseline in sum of the target lesion diameter per patient. CR = complete response; PR = partial response; SD = stable disease; PD = progressive diseaseBack to article page